Schering/Merck Zetia 6% Market Share Is 1% Ahead Of Goal
This article was originally published in The Pink Sheet Daily
Executive Summary
Prescription growth for the cholesterol drug Zetia has not come at the expense of the Zetia/Zocor fixed-dose combination Vytorin, Schering says. The penetration rate for Vytorin on managed care formularies is over 75%, the company says.
You may also be interested in...
Vytorin, Zetia Labeling Adds Precaution On Cyclosporine Coadministration
Revised labeling for the Merck/Schering-Plough products recommends caution when coadministering ezetimibe and cyclosporine. In healthy patients, coadministration of cyclosporine and ezetimibe was associated with a 15% increase in cyclosporine AUC, labeling states.
Vytorin, Zetia Labeling Adds Precaution On Cyclosporine Coadministration
Revised labeling for the Merck/Schering-Plough products recommends caution when coadministering ezetimibe and cyclosporine. In healthy patients, coadministration of cyclosporine and ezetimibe was associated with a 15% increase in cyclosporine AUC, labeling states.
Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition
Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market